ReviewChinese medical journal2020
Recent progress in Helicobacter pylori treatment.
Review in Chinese medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients withFrontiers in microbiology · 2025Pooled it
- Minocycline in the eradication ofWorld journal of gastroenterology · 2024Pooled it
- Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- Vitamins andFrontiers in nutrition · 2021Pooled it
- Different dose of new generation proton pump inhibitors for the treatment ofInternational journal of immunopathology and pharmacologyPooled it
- Vonoprazan-based dual therapy with amoxicillin or doxycycline versus bismuth-containing quadruple therapy forFrontiers in cellular and infection microbiology · 2026Trial
- [Molecular mechanisms of chronic gastric mucosal inflammation induced byZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Beyond Urease: New Potential Enzymatic Targets inACS omega · 2026Review
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Barriers toBMJ open · 2026Article
- Eco-Friendly Synthesis and Characterization ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Eradication ofIranian journal of microbiology · 2025Article
- Burden of Helicobacter pylori in Duodenal Ulcer Disease: Evidence From a Tertiary Hospital in Chennai, India.Cureus · 2025Article
- 40 years after the discovery ofiMetaOmics · 2025Article
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- A scoping review of worldwide guidelines for diagnosis and treatment of Helicobacter pylori infection.Systematic reviews · 2025Article
- Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
- Stimulus-responsive biomaterials for Helicobacter pylori eradication.Journal of advanced research · 2024Review
- Anti-Helicobacter pylori activity of nanocomposites from chitosan/broccoli mucilage/selenium nanoparticles.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main challenge in the field of Helicobacter pylori (H. pylori) infection is antibiotic resistance, which influences the efficacy of eradication regimens. Bismuth-containing quadruple therapy has been confirmed as an effective regimen for eradicating H. pylori, especially in strains with antibiotic resistance. High-dose proton-pump inhibitor-amoxicillin dual therapy could decrease the use of unnecessary antibiotics, which is a promising alternative approach. Adjuvant therapy (specific probiotic or vitamin) also showed good results, although more evidence is needed. Novel anti-H. pylori drugs are needed, and the establishment of the H. pylori database is an effective way to acknowledge the real-time information of H. pylori management. This review provides the recent progress of H. pylori treatment, and further studies are needed to address the role of different regimens in improving H. pylori eradication rate, especially in strains with antibiotics resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.